Last reviewed · How we verify

NCT04039672: MELANOPREDICT

Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma

Completed NA Last updated 10 October 2024
What this trial tests

NA trial testing Skin biopsy in Melanoma in 10 participants. Completed in 2 July 2024.

Timeline
2 April 2021
Primary endpoint
2 July 2024
2 July 2024

Quick facts

Lead sponsorHospices Civils de Lyon
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment10
Start date2 April 2021
Primary completion2 July 2024
Estimated completion2 July 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an interventional mono-centric study in patients with BRAF mutated metastatic melanoma treated with BRAF/MEK inhibitors. The aim of the study is to test the grafting of patient tumoral cells in avian embryo and develop a predictive in vivo model for patient treatment response.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Skin biopsy

Trials testing the same drug.

Other recruiting trials for Melanoma

Currently open trials in the same condition.

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04039672.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing